Compare VanEck Junior Gold Miners (GDXJ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Johnson & Johnson — how do they compare? VanEck Junior Gold Miners trades at $92.93, while Johnson & Johnson trades at $249.47 (market cap $594.63B). The key difference: Johnson & Johnson pays a 2.17% dividend while VanEck Junior Gold Miners pays none, and Johnson & Johnson is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| GDXJ | JNJ | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $267.24 |
52-Week Low | $64.22 | $162.98 |
Market Cap | — | $594.63B |
Volume | — | 6,156,228 |
Enterprise Value | — | $627.57B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $93.33, down 5.12% in the last 24 hours amid a bearish technical signal. Technical indicators show moving averages are bearish, while oscillators are neutral. Recent news highlights underperformance versus peers and questions about its small-cap focus. Key support lies at $91, with resistance at $98.
The outlook for GDXJ is cautious due to weak technicals and negative sentiment. Risks include Federal Reserve rate hike expectations and competition from other gold ETFs. Analyst consensus is bearish, with limited fundamental data available. Investors should weigh macroeconomic factors affecting gold miners before considering a position.
Johnson & Johnson (JNJ) trades at $253.85, down 1.52% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 earnings of $2.70 per share, beating estimates, and raised its full-year 2026 outlook. Revenue grew 6.6% annually in Q2 2026, driven by strength in Innovative Medicine and new product launches, though MedTech sales slightly missed expectations.
JNJ offers a compelling investment case with a 64-year dividend king status, robust profitability, and raised guidance, but faces risks from patent expirations and competitive pressures. Analyst consensus is bullish with a $281 price target, suggesting ~11% upside, supported by strong institutional confidence and innovation in AI and robotics targeting $100 billion revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
